The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 41 | 491.3x | 20.1x | Near average | |
Growth | 38 | 9.2% | 5.6% | Near average | |
Quality | 50 | 0.1% | 7.6% | Near average | |
Safety | 29 | 143.1x | 0.4x | Below average | |
Capital Return | 88 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Jazz Pharmaceuticals plc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Jazz Pharmaceuticals plc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
JAZZ stock has seen a gradual improvement in analyst optimism over the past 30 days, with the average price target rising by 0.93% to reach $257.63, supported by 8 new analysts initiating coverage on the stock. This momentum reflects stability in positive outlooks, with UBS upgrading its rating to 'Buy' and major institutions such as Barclays and Morgan Stanley maintaining their high ratings, indicating growing institutional confidence in future financial performance.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.